AP NEWS
Click to copy
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Kezar Life Sciences Announces Presentations at Two Upcoming Investor Conferences

May 14, 2019

SOUTH SAN FRANCISCO, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that members of the senior management team will present in two upcoming investor conferences. The details of the presentations are as follows:

RBC Capital Markets 2019 Healthcare ConferencePresentation: Tuesday, May 21, 2019 at 9:00 am EDTPresenters: Marc Belsky, Chief Financial Officer, and Niti Goel, M.D., Chief Medical Officer

Jefferies 2019 Healthcare ConferencePresentation: Wednesday, June 5, 2019 at 9:30 am EDTPresenters: John Fowler, Chief Executive Officer, Christopher Kirk, Ph.D., President & Chief Scientific Officer, and Niti Goel, M.D., Chief Medical Officer

The presentations will be webcasted and may be accessed at the “Events & Presentations” section of the Company’s website at http://investors.kezarlifesciences.com/events. Kezar Life Sciences will maintain an archived replay of the webcast on its website for 30 days after the conference.

About Kezar Life Sciences

Based in South San Francisco, Kezar Life Sciences is a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Kezar is translating its innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe and underserved autoimmune diseases. Additionally, Kezar plans to nominate an initial clinical candidate for the treatment of cancer from its protein secretion program before the end of the year. For more information, visit www.kezarlifesciences.com.

CONTACT:Celia EconomidesSVP, Strategy & External Affairsceconomides@kezarbio.com

All contents © copyright 2019 The Associated Press. All rights reserved.